MLL Munich Leukemia Laboratory buys Fluidigm (Caltech) Access Array™ & Ep1™ Systems (11/16/2010)

Fluidigm was founded in 1999 to commercialize IFC technology developed by Dr. Stephen Quake when he was at Caltech.

From the company’s press release:
Fluidigm Corporation announced today that MLL Munich Leukemia Laboratory (www.mll.com) has purchased Access Array™ and EP1™ Systems. The Access Array System is being used in combination with Roche’s 454 GS FLX and GS Junior sequencing instruments, enabling high-throughput targeted deep-resequencing analyses. The EP1 System is being used for rare mutation detection studies and minimal residual disease investigations. read full press release

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: